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Congenital muscular dystrophy type 1A is caused by mutations in the LAMA2 gene, which encodes the a2-chain of laminin. We
report two patients with partial laminin-a2 deﬁciency and atypical phenotypes, one with almost exclusive central nervous system
involvement (cognitive impairment and refractory epilepsy) and the second with marked cardiac dysfunction, rigid spine syndrome
and limb-girdle weakness. Patients underwent clinical, histopathological, imaging and genetic studies. Both cases have two
heterozygous LAMA2 variants sharing a potentially pathogenic missense mutation c.2461A>C (p.Thr821Pro) located in exon 18.
Brain MRI was instrumental for the diagnosis, since muscular examination and motor achievements were normal in the ﬁrst patient
and there was a severe cardiac involvement in the second. The clinical phenotype of the patients is markedly diﬀerent which could in
part be explained by the diﬀerent combination of mutations types (two missense versus a missense and a truncating mutation).
 2014 Elsevier B.V. All rights reserved.
Keywords: Laminin a2-chain; Merosin; Cardiomyopathy; Epilepsy; Congenital muscular dystrophy 1A1. Introduction
Mutations in LAMA2, encoding the a2-subunit of the
extracellular matrix protein laminin, are normally
associated with muscular dystrophy and white matter
abnormalities of the central nervous system (CNS).http://dx.doi.org/10.1016/j.nmd.2014.01.004
0960-8966/ 2014 Elsevier B.V. All rights reserved.
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dx.doi.org/10.1016/j.nmd.2014.01.004Classical congenital muscular dystrophy type 1A
(MDC1A) is characterized by severe generalized muscle
weakness, joint contractures and peripheral neuropathy
[1]. Primary partial laminin-a2 deﬁciency is associated
with a less severe phenotype and with clinical and genetic
heterogeneity [2–4].
In cardiac muscle, through its interactions with the
a2-chain of laminin 211, a-dystroglycan makes an
important connection to the extracellular matrix,
forming a link between the sarcolemma and theo patients with LAMA2 mutations, Neuromuscul Disord (2014), http://
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ARTICLE IN PRESSextracellular matrix [5]. Symptomatic and subclinical
cardiac involvement has been previously reported,
notably in typical cases with absent laminin-a2 staining
[4,6,7]. Regarding partial defects, cardiac involvement
was documented only in one patient [8].
Previous studies indicate that laminin deﬁciency delays
oligodendrocyte maturation through dysregulation of
critical developmental signaling pathways [9]. Laminin-a2
binds to b1-integrin and is distributed punctately on
cortical neuronal processes [10]. Cerebral white-matter
changes are typical; cortical dysplasia and polymicrogyria
are seldom seen. Most patients are cognitively normal, but
epilepsy and mental retardation have been described [11].
We report two patients with atypical phenotypes for
primary partial laminin-a2 deﬁciency. The ﬁrst case is
remarkable for the predominant CNS involvement with
normal muscular strength and the second had an
unusually severe cardiac involvement.
2. Case reports
2.1. Patient 1
This patient is the second child of healthy unrelated
parents and he was born after an uneventfulFig. 1. T2-weighted axial (A) and coronal (B) brain MRI of patient 1 at age
patient 1: diﬀuse slowing of background activity; bilateral paroxysms, stronger
patient 2 with extensive white matter hyperintensities; (F) lumbar hyperlordosis
patient 2.
Please cite this article in press as: Marques J et al., Atypical phenotype in tw
dx.doi.org/10.1016/j.nmd.2014.01.004pregnancy. Macrocephaly (3SD) was detected in the
ﬁrst year of life. Refractory epilepsy associated with
progressive cognitive regression started by the age of 6,
with atypical absences, myoclonic and atonic seizures.
Physical exam revealed macrocephaly and bilateral
divergent strabismus. Motor complaints were never
reported. He had normal muscular strength, tone and
deep tendon reﬂexes. His gait was normal, with
preserved coordination, and he was able to run, climb
stairs and ride his bike. Brain magnetic resonance
imaging (MRI) showed an area of agyria in the
occipital cortex. In T2-weighted images, extensive white
matter abnormalities, swelling and widening of gyri,
mainly frontal, were detected (Fig. 1A and B). Serial
electroencephalograms (EEG) revealed bilateral
multifocal paroxysmal activity, suggestive of
symptomatic epilepsy (Fig. 1C). LAMA2 gene study
was performed after extensive metabolic and genetic
workup, given the occipital agyria and typical white
matter abnormalities [12]. The highest creatine kinase
(CK) value detected was 1589 UI/L. Electromyography
(EMG), nerve conduction study and echocardiogram
were unremarkable.
Epilepsy was initially controlled, but rapidly became
refractory, with progressive cognitive impairment and15; note the occipital agyria and white matter hyperintensity; (C) EEG of
in the anterior regions. (D and E) Axial FLAIR T2-weighted brain MRI of
in patient 2; (G) tendinous retractions in patient 2; (H) scapular winging in
o patients with LAMA2 mutations, Neuromuscul Disord (2014), http://
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ARTICLE IN PRESSloss of expressive language. Motor function remains
normal at age 21. Ruﬁnamide signiﬁcantly reduced the
severity and frequency of atonic seizures.2.2. Patient 2
This 55 year-old male patient was a single child of a
healthy, non-consanguineous couple without family
history of neuromuscular diseases. He presented delayed
developmental motor milestones: he started walking after
the age of 2 and always had diﬃculty running. By the
age of 47 he sought medical attention, complaining of
slowly progressive proximal muscle weakness and
frequent falls, starting in his early forties. His
neurological exam was notable for shoulder and pelvic
girdle weakness, weak knee ﬂexion and extension, and
positive Gowers’ maneuver; muscular atrophy with
scapular winging (Fig. 1H); lumbar hyperlordosis
(Fig. 1F) and dorsolumbar scoliosis. A rigid spine
syndrome was noted as well as multiple tendinous
retractions (Fig. 1G). Brain MRI showed typical white
matter abnormalities (Fig. 1D and E). CK values were
351 UI/L. EMG was consistent with a myopathic
process. Echocardiogram showed impaired left
ventricular contractility and mitral valve prolapse. ECG
Holter was normal. A slowly but progressive worsening
of his motor function was noted over the years; he
remains ambulant with bilateral support. Cardiac
function has clearly declined and he developed dilated
cardiomyopathy with dysfunction of the left ventricle
contractility (shortening fraction 18%), marked dilatationFig. 2. Histologic and molecular studies performed in both patients. (A) Patie
variability of ﬁber diameter; (B) patient 1, gomori trichrome staining (10); (C
ﬁber diameter with round atrophic ﬁbers, dispersed in the fascicles or in gro
reaction (pH 9.4; 10). Type 1 ﬁbers predominated; (E) partial and irregular
irregular laminin-a2 labeling in patient 2 muscle specimen (20); (G) normal
muscular sample by comparison to a control. P = patient; C = control muscle
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dx.doi.org/10.1016/j.nmd.2014.01.004of the left ventricle and congestive heart failure NYHA
class II–III.
3. Muscle histology
Specimens were obtained by open left deltoid muscle
biopsy, frozen and stained using standard techniques.
Additionally, 6 lm sections were immunolabeled with
antibodies targeting the 300 kDa N-terminal fragment of
laminin-a2 (NCL-merosin, Novocastra). Histological
analysis in both cases revealed unspeciﬁc signs of
muscular dystrophy (Fig. 2A–D). Immunohistochemistry
labeling for dystrophin, sarcoglycans and dysferlin was
normal, but a partial and irregular labeling for laminin-
a2 was documented in both specimens (Fig. 2E–G).
4. Molecular studies
4.1. Genomic DNA analysis
LAMA2 gene sequencing was performed according to
Oliveira et al. [2], where all coding and adjacent intronic
sequences were analyzed. Sequence variants were
described according to the Human Genome Variation
Society guidelines for mutation nomenclature (version
2.0) [13] and the reference sequence with accession
NM_000426.3. Two heterozygous missense mutations
were identiﬁed in patient 1, namely c.812C>T
(p.Thr271Ile) in exon 5 and c.2461A>C (p.Thr821Pro) in
exon 18 (Fig. 3). Family studies conﬁrmed that these
were allelic in the patient. Heterozygosity was also found
in patient 2, who presented the missense mutationnt 1, hematoxylin and eosin staining (10) discloses a mild increase in the
) patient 2, hematoxylin and eosin (10), revealing increased variability of
ups in the same area and frequent central nuclei; (D) patient 2, ATPase
laminin-a2 labeling in patient 1 muscle specimen (20); (F) partial and
control for laminin-a2 labeling. (H) Immunoblotting analysis of patient 1
.
o patients with LAMA2 mutations, Neuromuscul Disord (2014), http://
Fig. 3. Genetic studies performed in both patients. (A) gDNA sequencing results showing the two novel LAMA2 mutations (arrows indicate changes)
detected in heterozygosity in patient 1 (P1). (B) mRNA studies in patient 1, excluded possible splicing defects in the vicinity of the mutations. (C)
Heterozygous mutations identiﬁed at the gDNA level in patient 2 (P2); the ﬁrst in common with patient 1 and the second found to be a previously reported
splicing mutation in intron 36 (c.5234+1G>A).
4 J. Marques et al. /Neuromuscular Disorders xxx (2014) xxx–xxx
ARTICLE IN PRESSc.2461A>C (p.Thr821Pro), in common with patient 1, and
the splicing mutation c.5234+1G>A (p.Val1765Serfs*21)
known to cause skipping of exon 36 [2].
Population screening for these missense variants was
carried out by direct sequencing of exon 5 in the case of
c.812C>T and by high resolution melting curve analysis
(hrMCA) of exon 18 in the case of c.2461A>C. Neither
variants were detected in 300 control alleles,
corroborating their pathogenic nature.4.2. cDNA studies
Knowing that variants that are predictably missense can
actually induce splicing defects [14], and since both variants
are located in the vicinity of splice sites, we evaluated their
possible eﬀects on pre-mRNA processing. Transcript
analysis was performed in a cryopreserved muscle
specimen from patient 1, using primers designed
speciﬁcally for the regions of interest. Results showed
that neither appeared to have an eﬀect on mRNA
splicing (no exon skipping or cryptic splice site
activation) and that bi-allelic expression was evidenced
with both mutations detected in heterozygosity (Fig. 3).4.3. Western Blotting
Laminin-a2, a-dystroglycan and b-dystroglycan
expression in a muscle sample from patient 1 was
assessed by Western Blotting (WB) analysis using
monoclonal antibodies against the 80 kDa C-terminal
segment of laminin-a2 (MAB1922, Chemicon, Millipore,
Temecula, CA), a glycosylated epitope of a-dystroglycan
(VIA4-1, Upstate, Millipore, Temecula, CA) and b-
dystroglycan (NCL-b-DG, Novocastra, Leica
Microsystems, Newcastle Upon Tyne, UK). The latterPlease cite this article in press as: Marques J et al., Atypical phenotype in tw
dx.doi.org/10.1016/j.nmd.2014.01.004was used as an internal control. The WB procedure was
adapted from the protocol reported by Anderson et al.
[15]. For the purpose of densitometry, protein loading
was normalized with the myosin band in the post-blotted
gel. Immunoblot analysis revealed complete absence of
merosin with the anti-80 kDa antibody. A 75% reduction
was detected in a-dystroglycan expression by comparison
with the control (Fig. 2, H), possibly due to technical
issues related with the heterogeneous glycosylation
pattern of the epitope recognized by the VIA4-1 antibody.4.4. Bioinformatic analysis of missense variants
Besides the in vitro experiments described above we also
assessed the pathogenicity of the missense variants using a
diversity of bioinformatic tools and databases. As depicted
in table S1 in supplementary data, all algorithms
consistently suggested a deleterious eﬀect for these
mutations. In addition, the mutations c.2461A>C and
c.812C>T were not present in SNP databanks including
dbSNP, 1000 Genomes and Exome Variant Server.5. Discussion
We report two patients with partial laminin-a2 deﬁciency
and atypical phenotypes. The ﬁrst patient had epileptic
encephalopathy with normal muscular examination. The
second case had a limb-girdle muscular dystrophy
phenotype with unusually severe cardiac involvement.
Brain imaging was instrumental for diagnosis. Two
missense mutations were found in patient 1, located in the
N-terminus of laminin-a2; p.Thr271Ile in domain LN
(laminin N-terminal) and p.Thr821Pro in domain LEb).
Regarding patient 2, two heterozygous mutations were
detected: the same missense mutation c.2461A>Co patients with LAMA2 mutations, Neuromuscul Disord (2014), http://
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c.5234+1G>A (p.Val1765Serfs*21) in intron 36, which
has been previously described [2]. The clinical phenotype
of both patients is markedly diﬀerent which could only in
part be explained by the diﬀerent allelic combination of
mutations detected in each case. In the Leiden Muscular
Dystrophy Pages (http://www.dmd.nl/LAMA2), we have
found an entry for the c.2461A>C variant, but reported
as being of unknown pathogenicity. Interestingly, this
mutation was reported in this database in together with
the c.5234+1G>A mutation, the same combination as in
patient 2. However, the phenotypes of both patients seem
to diﬀer signiﬁcantly (seizures, abnormal white matter,
and cervical spine fusion as indicated in the Leiden
database, without mention of a cardiac phenotype).
Reports of MDC1A (MIM: 607855) patients with severe
cognitive impairment are very scarce and the severity of
CNS involvement combined with absent muscular
complaints, as described here for patient 1, is a new form
of presentation of this disorder. In previous series of
patients [7] there was no apparent correlation between
mental retardation and severity of weakness, suggesting
that diﬀerent mechanisms contribute to muscular and
CNS involvement. Ruﬁnamide was shown to be eﬀective
in epileptic encephalopathies other than Lennox–Gastaut
syndrome, particularly in patients with drop-attacks and
(bi)frontal spike-wave discharges, matching our patient’s
clinical features [16].
Cardiac involvement in laminin-a2 deﬁciency has been
largely underreported. One study speciﬁcally addressed
the cardiac involvement in children with laminin-a2
deﬁciency [6]. A cohort of 16 children with congenital
muscular dystrophy was studied (6 with MDC1A) where
two children with signiﬁcant left ventricular dysfunction
had complete laminin-a2 deﬁciency. In another series of
51 patients with MDC1A [4], 15 had cardiac assessment,
of whom 5, with complete laminin-a2 deﬁciency, had
cardiac abnormalities. Documentation on cardiac status
was unavailable for the remaining patients. In the largest
bibliographical review (248 published patients with
abnormal immunohistochemical staining for laminin-a2)
cardiac function was described in 20 [7]. Cardiac
dysfunction was reported in 7 patients (7/20, 35%), of
whom 4 were asymptomatic. Cardiac abnormalities
varied, including right bundle branch block, dilated
cardiomyopathy and “borderline changes in cardiac
function”.
To the best of our knowledge, only one case of partial
defect of laminin-a2 with cardiac involvement was
previously reported [8]. Long-term evaluation led to a
diagnosis of dilated cardiomyopathy with ventricular
arrhythmias, requiring implantation of an intracardiac
deﬁbrillator. In this patient, LAMA2 gene analysis
revealed two diﬀerent mutations, a missense mutation in
exon 29 (c.4405T>C, p.Cys1469Arg) and a nonsense
mutation in exon 31 (c.4645C>T, p.Arg1549*).Please cite this article in press as: Marques J et al., Atypical phenotype in tw
dx.doi.org/10.1016/j.nmd.2014.01.004We want to highlight the need for cardiac status
assessment in this disorder, given the potential of severe
cardiac involvement, even in patients with residual
expression of the laminin-a2 chain.
This report widens the clinical presentation associated
with genetic defects in LAMA2. These cases are probably
under-diagnosed and seldom reported in the literature,
especially when only subtle changes in laminin-a2 chain
are detected in IHC studies. Considering the interplay
role of laminin-a2 in the basal membrane and
extracellular matrix, it is conceivable that mutations in
this protein may only aﬀect the interaction with other
proteins maintaining at least partial interaction with a-
dystroglycan, and leading to other phenotypes not
directly related with muscle weakness.Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.nmd.2014.01.004.
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